Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- CMPX
- Price
- 2.10
- Stock movement down
- -0.01 (-0.47%)
- Company name
- Compass Therapeutics Inc.
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 288.94M
- Ent value
- 262.89M
- Price/Sales
- 78.22
- Price/Book
- 2.09
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- 40.47%
- 3 year return
- -6.75%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-05-29
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
CMPX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 78.22 |
| Price to Book | 2.09 |
| EV to Sales | 71.17 |
iO Charts is a Seeking Alpha partner
Compass Therapeutics' lead candidate, tovecimig, shows mixed data in various trials, with a significant upcoming phase 3 trial in BTC expected. Learn more on CMPX stock here.
February 24, 2025
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 137.59M |
| EPS (TTM) | -0.35 |
| FCF per share (TTM) | -0.35 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 3.69M |
| Gross profit (TTM) | 2.76M |
| Operating income (TTM) | -55.45M |
| Net income (TTM) | -47.76M |
| EPS (TTM) | -0.35 |
| EPS (1y forward) | -0.41 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 74.80% |
| Operating margin (TTM) | -1501.00% |
| Profit margin (TTM) | -1292.88% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 36.80M |
| Net receivables | 0.00 |
| Total current assets | 141.14M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 149.15M |
| Accounts payable | 960.00K |
| Short/Current long term debt | 6.88M |
| Total current liabilities | 4.43M |
| Total liabilities | 10.75M |
| Shareholder's equity | 138.40M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -48.05M |
| Capital expenditures (TTM) | 53.00K |
| Free cash flow (TTM) | -48.10M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -34.51% |
| Return on Assets | -32.02% |
| Return on Invested Capital | -34.37% |
| Cash Return on Invested Capital | -34.62% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 2.11 |
| Daily high | 2.23 |
| Daily low | 2.09 |
| Daily Volume | 493K |
| All-time high | 8.80 |
| 1y analyst estimate | 8.00 |
| Beta | 0.75 |
| EPS (TTM) | -0.35 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| CMPX | S&P500 | |
| Current price drop from All-time high | -76.14% | -4.11% |
| Highest price drop | -90.91% | -56.47% |
| Date of highest drop | 5 Jul 2024 | 9 Mar 2009 |
| Avg drop from high | -70.09% | -11.06% |
| Avg time to new high | 336 days | 12 days |
| Max time to new high | 1005 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
288.94M
Marketcap category
Small-cap
Description
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Employees
32
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page